The Phase 1 data readout for MRT-8102 in ASCVD is a binary catalyst for GLUE. Positive safety and biomarker modulation could open a large cardiovascular market and validate the MGD platform beyond oncology. Negative or equivocal data would likely pressure the stock. Monitor the October 1 webcast for dose-dependent efficacy and safety signals.
Price Chart
Executive Summary
Monte Rosa Therapeutics announced a conference call and webcast to review clinical results from the GFORCE-1 Phase 1 study of its NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease risk. The presentation will include safety and activity data across multiple dose levels after 4 weeks of treatment, as well as data on modulation of pathogenic drivers of atherosclerotic cardiovascular disease. This is a data readout event for a clinical-stage biotech with no disclosed financial results or regulatory decision.
Key Facts
- Monte Rosa will host a conference call and webcast on October 1, 2026 at 8:00 a.m. ET.
- The presentation will review clinical results from the GFORCE-1 Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader.
- Data will include safety and activity across multiple dose levels after 4 weeks of treatment.
- The presentation will showcase data on modulation of multiple pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD).
- MRT-8102 is a first-in-class candidate for cardiovascular disease, a new indication for the company beyond its core oncology/immunology pipeline.
Financial Impact
No financial data disclosed; impact depends on Phase 1 data quality and safety/efficacy signals.
Risk Factors
- Phase 1 data may show insufficient efficacy or safety concerns, leading to program de-prioritization.
- Cardiovascular disease is a new therapeutic area for Monte Rosa; lack of precedent for MGDs in ASCVD increases uncertainty.
- Small sample size and short 4-week treatment duration limit interpretability of the data.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372369 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | 8-K | $11.26 | awaiting T+60 | — | $10.46 (−7.10%) |
Sep 30, 2026 25d ago | Press Release | $11.26 | awaiting T+60 | — | $10.46 (−7.10%) |
Aug 6, 2026 11w ago | 8-K | $15.71 | awaiting T+60 | — | $10.46 (−33.42%) |
Jul 17, 2026 14w ago | Insider Cluster | $23.48 $9.89 | ▼ −57.88% | ▼ −62.72% | $10.46 (−55.45%) |
Jul 7, 2026 15w ago | Insider Cluster | $24.06 $11.93 | ▼ −50.42% | ▼ −52.73% | $10.46 (−56.53%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.46 (−56.79%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.46 (−56.79%) |
Jun 29, 2026 16w ago | 144 | $24.20 $11.89 | ▼ −50.87% | ▼ −54.43% | $10.46 (−56.78%) |
Jun 25, 2026 17w ago | Insider Cluster | $22.29 $12.60 | ▼ −43.47% | ▼ −49.56% | $10.46 (−53.07%) |
Jun 2, 2026 20w ago | Insider Cluster | $17.59 $14.32 | ▼ −18.59% | ▼ −21.09% | $10.46 (−40.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers